Psilocybin is under clinical development by Reset Pharmaceuticals and currently in Phase III for Anxiety Disorders. According to GlobalData, Phase III drugs for Anxiety Disorders have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin overview
Psilocybin is under development for the treatment of anxiety and depression. The drug candidate is a tryptamine alkaloid that acts by targeting 5-hydroxytryptamine receptor 1A (5HT1A) and 5HT2A receptors. It is administered through oral route.
Reset Pharmaceuticals overview
Reset Pharmaceuticals (Reset Pharma) is a biotechnology company focused on developing psilocybin and psychedelic therapies. Reset Pharma is headquartered in New York City, New York, the US.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
